NEW YORK, NY
Flatiron Health® today announced three Flatiron-authored abstracts have been accepted for poster discussion and presentations at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, to be held June 3-7.
“As demonstrated by our research at ASCO this year, we are at the forefront of our industry to improve patient lives through the power of integrated evidence, and are committed to advance equitable care for all patients,” said Carolyn Starrett, Flatiron CEO. “At Flatiron, we are reimagining the infrastructure of cancer care. We bring together science, technology, and medicine to transform possibilities into results and solve critical challenges with our partners.”
Highlights include:
-
an investigation that uses one of the largest real-world datasets with a telemedicine variable available to assess patterns of use among patients with cancer during the COVID pandemic, illuminating health inequityFlatiron Health Announces Research to be Presented at American Society of Clinical Oncology 2022 Annual Meeting
-
a study that uses integrated evidence to quantify the clinical value of multi-gene testing in early-stage lung adenocarcinoma, showcasing potential benefit in treatment decision-making
-
a study that evaluates and understands the value of ctDNA as a non-invasive tool to treat patients with advanced NSCLC by leveraging the Flatiron Health-Foundation Medicine Clinico-Genomic Database
Poster Discussions and Presentations
First author: Jenny Guadamuz, Xiaoliang Wang, Trevor J. Royce, Gregory S. Calip
Abstract: 6511
A real-world evidence study quantifying the clinical value of multi-gene testing in early-stage lung adenocarcinoma (LUAD)
Partner: Foundation Medicine
First author: Nathan Pennell, Lianliang Zhang, Katherine T. Lofgren, Bharathi Muthusamy, Emily Castellanos, Karen Schwed, Oliver Humblet, Alexa B. Schrock, Geoffrey R. Oxnard
Abstract: 8525
Partner: Foundation Medicine
First author: Benjamin Besse, Russell W. Madison, Cheryl Cho-Phan, Jermey Snider, Tamara Snow, Filippo G Dall’Olio, Khaled Tolba, Alexa B. Schrock, Geoffrey R. Oxnard
Abstract: 9045
###
About Flatiron Health
Flatiron Health is a healthtech company expanding the possibilities for point of care solutions in oncology and using data for good to power smarter care for every person with cancer. Through machine learning and AI, real-world evidence, and breakthroughs in clinical trials, we continue to transform patients’ real-life experiences into knowledge and create a more modern, connected oncology ecosystem. Flatiron Health is an independent affiliate of the Roche Group.
